Systemic Juvenile Idiopathic Arthritis clinical trials

Explore recruiting systemic juvenile idiopathic arthritis clinical trials.

Recruiting systemic juvenile idiopathic arthritis studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Systemic Juvenile Idiopathic Arthritis trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

I4V-MC-JAHU: Open-Label, Randomized Study with a Tocilizumab Reference Arm to Evaluate Safety, Efficacy and Pharmacokinetics of Baricitinib in Children from 1 to Less Than 18 Years of Age with Systemic Juvenile Idiopathic Arthritis

Belgium, Poland, Czechia, France, Austria, Italy +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Apremilast in Children From 5 to Less Than 18 Years of Age With Active Juvenile Psoriatic Arthritis (PEAPOD)

France, Portugal, Belgium, Lithuania, Germany, Netherlands +6 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Biomarker-guided treatment-and-stop-strategy for recombinant IL-1receptor antagonist (anakinra) in patients with systemic Juvenile Idiopathic Arthritis

Netherlands

Therapeutic use (Phase IV) EU CTIS Study details

An Open-label, Sequential, Ascending, Repeated Dose-finding Study of Sarilumab, Administered with Subcutaneous (SC) Injection, in Children and Adolescents, Aged 1 to 17 Years, with Systemic Juvenile Idiopathic Arthritis (sJIA), Followed by an Extension Phase. Name: SKYPS

Ireland, Germany, Finland, Italy, Spain, Bulgaria +5 more

Therapeutic exploratory (Phase II) EU CTIS Study details

A Two-cohort, Open-label, Single-arm, Multicenter Study to Evaluate Efficacy, Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of Emapalumab in Children and Adults with Macrophage Activation Syndrome (MAS) in Still's Disease (Including Systemic Juvenile Idiopathic Arthitis and Adult Onset Still's Disease) or with MAS in Systemic Lupus Erythematosus

Italy, Czechia, Netherlands

Phase II and Phase III (Integrated) EU CTIS Study details

A Phase 3, Multicenter, Open-label, Long-term Extension Study of Apremilast in Children 2 Years of Age or Older With Oral Ulcers Associated With Behçet’s Disease or 5 Years of Age or Older With Juvenile Psoriatic Arthritis

Spain, Italy, Greece

Therapeutic confirmatory (Phase III) EU CTIS Study details

Systemic Juvenile Idiopathic Arthritis trials by city

Systemic Juvenile Idiopathic Arthritis in Toronto Systemic Juvenile Idiopathic Arthritis in Vancouver Systemic Juvenile Idiopathic Arthritis in Montreal Systemic Juvenile Idiopathic Arthritis in Calgary Systemic Juvenile Idiopathic Arthritis in Edmonton Systemic Juvenile Idiopathic Arthritis in Ottawa Systemic Juvenile Idiopathic Arthritis in Winnipeg Systemic Juvenile Idiopathic Arthritis in Quebec City Systemic Juvenile Idiopathic Arthritis in Hamilton Systemic Juvenile Idiopathic Arthritis in Kitchener Systemic Juvenile Idiopathic Arthritis in London Systemic Juvenile Idiopathic Arthritis in Halifax Systemic Juvenile Idiopathic Arthritis in New York Systemic Juvenile Idiopathic Arthritis in Los Angeles Systemic Juvenile Idiopathic Arthritis in Chicago Systemic Juvenile Idiopathic Arthritis in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease